Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
Public ClinicalTrials.gov record NCT02853604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence. The purpose of the study was to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following cisplatin-based combination chemotherapy and radiation (CCRT) with curative intent in participants with HRLACC.
Study identification
- NCT ID
- NCT02853604
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 110 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2015 (Actual)
- Primary completion
- Jul 31, 2019 (Actual)
- Completion
- Jul 31, 2019 (Actual)
- Last update posted
- Mar 14, 2023
2015 – 2019
United States locations
- U.S. sites
- 41
- U.S. states
- 24
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | — | — |
| Site | Phoenix | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Duarte | California | — | — |
| Not listed | Long Beach | California | — | — |
| Site | Orange | California | 92868 | — |
| Not listed | Orange | California | — | — |
| Site | San Francisco | California | — | — |
| Site | Miami | Florida | — | — |
| Site | Tallahassee | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Maywood | Illinois | — | — |
| Site | Park Ridge | Illinois | — | — |
| Site | Indianapolis | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Scarborough | Maine | — | — |
| Site | Baltimore | Maryland | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Site | Omaha | Nebraska | — | — |
| Site | Las Vegas | Nevada | — | — |
| Site | Hackensack | New Jersey | — | — |
| Site | Newark | New Jersey | 07103 | — |
| Not listed | Albany | New York | 12208 | — |
| Site | Brooklyn | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Site | Cincinnati | Ohio | 45219 | — |
| Site | Hilliard | Ohio | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Site | Dallas | Texas | — | — |
| Site | Galveston | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02853604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2023 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02853604 live on ClinicalTrials.gov.